Roche will start a new global Phase 3 trial for Sarepta Therapeutics’ Duchenne muscular dystrophy gene therapy Elevidys after Europe delivered a negative opinion. The study plans to randomize about 100 early ambulatory boys to Elevidys or placebo over 72 weeks, using “time to rise” as the primary objective and aiming to produce evidence for a revised European submission.